Resapp Health Stock

Resapp Health FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Resapp Health (RAP.AX) as of Sep 4, 2026 is 58.85 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 84.29 % — a change of -30.18% (lower).

FCF Conversion

58.85 %

YoY

-30.18%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Resapp Health is 2026 58.85 % . FCF Conversion Rate (FCF/EBITDA) of Resapp Health was 2025 84.29 % . It decreases by -30.18% lower compared to the previous year.

The Resapp Health FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
79.71 AUD
Jan 1, 2016
75.64 AUD
Jan 1, 2017
54.28 AUD
Jan 1, 2018
78.83 AUD
Jan 1, 2019
89.85 AUD
Jan 1, 2020
49.65 AUD
Jan 1, 2021
84.29 AUD
Jan 1, 2022
58.85 AUD
The Resapp Health FCF Conversion history
YEARFCF ConversionYoY
58.85 %-30.18%
84.29 %+69.76%
49.65 %-44.74%
89.85 %+13.97%
78.83 %+45.23%
54.28 %-28.23%
75.64 %-5.10%
79.71 %+32.08%
60.34 %
Access this data via the Eulerpool API

Resapp Health Stock analysis

What does Resapp Health do? ResApp Health Ltd is an Australian company that focuses on the development of digital diagnostic and treatment solutions in the field of respiratory diseases. The company was founded in 2014 by Tony Keating and Philippa Lewis, both of whom have significant experience in the medical technology industry. The company aims to improve and simplify the diagnosis of respiratory diseases by developing a diagnosis based on cough and breath sounds. To achieve this, the company has developed an intelligent system based on machine learning and artificial intelligence that analyzes individual sound waves and provides an accurate diagnostic capability. ResApp Health's business model is based on the development of digital diagnostic and treatment solutions in the field of respiratory diseases, which are offered through various distribution channels. The company offers both mobile apps and clinical diagnostic systems. ResApp Health operates in various divisions at different levels. On the one hand, the company conducts research and development to continuously improve its products. On the other hand, it works closely with clinicians, scientists, and other industry experts to enable the best possible patient treatment. Products offered by ResApp Health include digital diagnostic systems in the field of respiratory diseases that function based on cough and breath sounds. The products are offered for use in both clinical practice and at home to enable fast and accurate diagnosis. Another important area in which ResApp Health operates is the treatment of respiratory diseases. The company offers digital therapy platforms tailored to the individual needs of patients, enabling improved therapy. ResApp Health has already achieved a number of important milestones. For example, in 2016, the company received CE marking for its digital diagnostic system, and in 2017, it completed a clinical study that demonstrated the system's high accuracy in diagnosing respiratory diseases. Overall, ResApp Health has great potential to play an important role in the field of diagnosis and treatment of respiratory diseases in the future. With a strong focus on research and development and close collaboration with industry experts, the company will continue to offer innovative solutions to improve patient health. Resapp Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resapp Health stock

FCF Conversion Rate (FCF/EBITDA) of Resapp Health is 58.85 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Resapp Health changed from 84.29 % to 58.85 %, representing a -30.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Resapp Health since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Resapp Health with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Resapp Health

All Key Metrics — Resapp Health